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Abstract
Background: The NAD-dependent deacetylase SIRT1 is a nutrient-sensitive coordinator of stress-tolerance, multiple
homeostatic processes and healthspan, while p53 is a stress-responsive transcription factor and our paramount tumour
suppressor. Thus, SIRT1-mediated inhibition of p53 has been identified as a key node in the common biology of cancer,
metabolism, development and ageing. However, precisely how SIRT1 integrates such diverse processes remains to be
elucidated.
Methodology/Principal Findings: Here we report that SIRT1 is alternatively spliced in mammals, generating a novel SIRT1
isoform: SIRT1-DExon8. We show that SIRT1-DExon8 is expressed widely throughout normal human and mouse tissues,
suggesting evolutionary conservation and critical function. Further studies demonstrate that the SIRT1-DExon8 isoform
retains minimal deacetylase activity and exhibits distinct stress sensitivity, RNA/protein stability, and protein-protein
interactions compared to classical SIRT1-Full-Length (SIRT1-FL). We also identify an auto-regulatory loop whereby SIRT1-
DExon8 can regulate p53, while in reciprocal p53 can influence SIRT1 splice variation.
Conclusions/Significance: We characterize the first alternative isoform of SIRT1 and demonstrate its evolutionary
conservation in mammalian tissues. The results also reveal a new level of inter-dependency between p53 and SIRT1, two
master regulators of multiple phenomena. Thus, previously-attributed SIRT1 functions may in fact be distributed between
SIRT1 isoforms, with important implications for SIRT1 functional studies and the current search for SIRT1-activating
therapeutics to combat age-related decline.
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Introduction
From yeast to humans, SIRT1 is a highly conserved protein
deacetylase and epigenetic sculptor of chromatin characteristics
[1–5]. SIRT1 also modulates multiple signaling factors. Thus
SIRT1 acts at several levels in concert to influence stress tolerance,
homeostasis, cell proliferation, circadian rhythm, differentiation,
development, and longevity [1–10]. Precisely how the SIRT1
protein governs so many processes has become the subject of
intense investigation. Importantly, SIRT1 couples target substrate
deacetylation with cellular metabolic status via its dependence on
levels of NAD+, a co-enzyme and metabolic intermediate
indicative of intracellular energy flux and redox potential
[1–4,7]. Recently, manipulation of SIRT1 activity has profoundly
influenced in vivo models of obesity, neuro-degeneration, diabetes,
cancer and aging [1–5,11,12]. Moreover, mammalian SIRT1
knockout is typically embryonic lethal, with surviving mice
displaying severe developmental abnormalities including exence-
phaly, sterility and heart/retinal defects [5,6,8].
The tumour suppressor p53 is mutated, deleted or indirectly
inactivated in the majority of human cancers, illustrating its
importance as ‘guardian of the genome’ [13–15]. In response to
diverse genotoxic stimuli, p53 instigates transcriptional programs
and protein-protein interactions which orchestrate DNA repair,
cell-cycle arrest, senescence or apoptosis, as appropriate [13–15].
p53 also influences key developmental decisions through pathways
which remain to be elucidated: the p53-dependent stress-response is
highly sensitive throughout embryonic tissues and p53 knockout
mice reveal embryonic abnormalities such as exencephaly [16–18].
Indeed, p53 acts as a fundamental barrier to cell immortalization,
blocking not only cancer-associated hyper-proliferation, but also
limiting de-differentiation of cells towards induced pluripotency
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Figure 1. Identification of a novel SIRT1 splice variant which is expressed widely in human tissues. (A) Human SIRT1 splice-variant
specific PCR primers and siRNA. Schematic displays human SIRT-FL coding mRNA sequence (based on NM_012238.3, GI: 13775598) plus loci of
primers used (arrows, below panel). Primers were used in pairs in a RT-PCR-based tiling approach to identify any Exon-skipping SIRT1 transcripts. The
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[19,20]. Similar to SIRT1, p53 has also recently been shown to
regulate metabolism in numerous ways [21]. However, basal p53
expression levels are low and limiting for function [16,22]. Crucially
therefore, considerable p53 accumulation is required to efficiently
execute p53-dependent functions. Modifying p53 function in-vivo
has profound outcomes: constitutive p53 hypo- or hyper-activity
adversely affects lifespan by increasing cancer incidence or
accelerating ageing respectively [23–26]. However, elevating p53
expression levels while maintaining normal regulation of its activity
can improve cancer resistence and delay aging [27–29]. Thus p53
levels and activity are fine-tuned by evolution to achieve the optimal
balance between cancer-resistance and longevity.
Acetylation represents an important p53 post-translational activa-
tion signal [30]. SIRT1 deacetylates and thereby represses p53
activity to protect cells from p53-dependent anti-proliferative
responses [31,32]. SIRT1 and p53 exert powerful and often opposing
influences in multiple overlapping processes, and therefore, the
SIRT1-p53 relationship may represent a key node in the common
biology of cancer, metabolism, development and ageing [31–33].
Here we report that human SIRT1 is alternatively spliced in a
manner which is stress-sensitive, p53-dependent and conserved in
mammals. The novel SIRT1 isoform, SIRT1-DExon8, displays
significant differences in stress-sensitivity, RNA/protein stability,
protein-protein interactions and deacetylase activity compared to
classical SIRT1-FL. The existence of alternative SIRT1 isoforms
with distinct characteristics provides insight into the complex role
of SIRT1 in vivo.
Results
SIRT1 is alternatively spliced, thereby amplifying its
functional potential
We hypothesised that SIRT1 mRNA might undergo splice
variation to generate diverse isoforms of distinct purpose. This was
assessed in human cells using multiple pairs of primers in a RT-
PCR-based tiling approach (Figure 1A), which revealed a novel
SIRT1 transcript skipping precisely the 558 bp of Exon8 only, to
produce an Exon7/9 splice junction (Figures 1A and S1), as
confirmed by sequencing the RT-PCR products (data not shown).
SIRT1-DExon8 lacks a portion of the reported deacetylase
catalytic domain [2] and is therefore predicted to exhibit
significantly altered deacetylase activity and NAD+-binding
efficiency compared to classical SIRT1-Full-Length (SIRT1-FL;
Figures 1A and 1B). The SIRT1-DExon8 splice variant was
ubiquitously expressed in all 12 normal human tissues tested, and
in a panel of 16 human epithelial cell lines of normal- or cancer-
origin (Figures 1C, 1D and S2); although SIRT1-FL was more
abundant in each case. However, the relative abundance of the
two transcripts showed significant tissue-specific variability. For
example, prominent SIRT1-DExon8 expression was detected
particularly in human brain, heart, fetal thymus and testis
(Figure 1D). It is notable that multiple SIRT1 functions have
previously been identified for neurons, cardiomyocytes and
gametogenesis [3–6,8]. The abundance of SIRT1-DExon8 also
differed sharply between fetal thymus versus adult thymus,
suggesting a developmental purpose, whereas SIRT1-FL abun-
dance was equivalent in fetal and adult thymus (Figure 1D).
Transcript-specific RT-PCR analysis also demonstrated SIRT1-
DExon8 expression in Mouse Embryonic Fibroblasts
(MEFs)(Figures 2A and S3). Ubiquitous expression of the
SIRT1-DExon8 splice variant was evident in a panel of 12 normal
mouse tissues, and in mouse cell lines of normal- or cancer-origin
(Figures 2B–2E). Similar to the pattern in human tissues, higher
levels of SIRT1-DExon8 were present in mouse brain, heart and
testis (compare: Figure 1D with 2B). Overall, the expression profile
of SIRT1-DExon8 was comparable in mouse and human tissues,
suggesting evolutionary conservation.
SIRT1-FL and SIRT1-DExon8 display distinct
characteristics
In contrast to SIRT1-FL, SIRT1-DExon8 expression was
sharply stress-inducible (Figures 3A and S4). UV-irradiation
dose-titration and time-course analysis revealed a rapid and
dose-dependent pulse of SIRT1-DExon8 expression (Figures 3A,
3B and S4). Pulse duration and amplitude were extended with
increasing stress severity, and SIRT1-DExon8 levels returned to
basal +48 hrs after stress-stimulation. This differential sensitivity to
stress-exposure was confirmed in vivo in mouse tissues (Figures 3C
and 3D). Whole-body c-irradiation of mice consistently induced
up-regulation of SIRT1-DExon8 expression, while SIRT1-FL
expression displayed no change or was moderately down-regulated
(Figures 3C and 3D). Note, since SIRT1-DExon8 stress-induction
consists of a transient pulse (Figures 3A and 3B), tissue-specific
kinetics may significantly influence the extent to which SIRT1-
DExon8 stress-induction is observed in each mouse tissue at the
2.5 hr timepoint used here (Figures 3C and 3D).
SIRT1-FL and SIRT1-DExon8 also displayed divergent RNA
stability following transcriptional inhibition (Figures 2E and S5).
Indeed, the results imply a post-transcriptional switch which
stimulates increased SIRT1-DExon8 production from a pre-existing
pool of immature SIRT1 pre-mRNA during transcriptional
inhibition. The dynamics of RNA processing are complex, however
our preliminary analyses indicate that protein levels of the SR-family
splicing factor SC35 are down-regulated by stress-exposure
(Figure 2F), while selective SC35 depletion also coincides with
SIRT1-DExon8 induction (Figure 2F). These results suggest a role for
SC35 in regulating the stress-sensitive splicing of SIRT1, consistent
with a previous report in mice [34], while SR-family splicing factors
are known targets of multiple stress-signaling kinases [35].
novel Exon7/9 splice junction and the target loci of siRNA which selectively target SIRT1-DExon8 (xD8*) or SIRT1-FL (xFL*) are shown above panel.
Exon8 is the largest SIRT1 coding Exon and translation of SIRT1-Exon9 remains in-frame in the SIRT1-DExon8 transcript. For human primer and siRNA
sequences see Figures S13 and S14. (B) Schematic of the 747-residue human SIRT1-Full-Length protein (SIRT1-FL; based on NP_036370) with the
Exon8-encoded region highlighted (558bp, 186 residues, black) within the catalytic deacetylase domain (240-664, red) as defined by Sinclair and
colleagues [2]. The conserved amino acid residues reported to be involved in NAD+-binding [48] and p53-binding [47] by SIRT1 homologues are listed
and their relative loci are indicated by vertical lines. The SIRT1-DExon8 protein (561 residues) lacks a central part of the catalytic domain (186 amino
acids), including three residues involved in NAD+-binding (underlined: 466, 467, 481). This is predicted to significantly alter NAD+-binding and
deacetylase catalytic efficiency of SIRT1-DExon8. Note that only 1 of the 14 residues mediating the p53-SIRT1 interaction lies within the Exon8-
encoded region and is therefore absent in the SIRT1-DExon8 protein (residue 469, underlined). The protein-binding regions for AROS and DBC-1 on
SIRT1-FL have been defined [44,45] and are indicated below the protein map. (C) Relative abundance of SIRT1-DExon8 (lower arrow) or SIRT1-FL
(upper arrow) across a range of normal human tissues. RT-PCR co-amplification of the two transcripts was performed with 250 ng total RNA from
each tissue and human primer pair Ex7F (Fwd) and Ex9R (Rvs) as in (A) above. (D) SIRT1-FL versus SIRT1-DExon8 expression across a range of normal
human tissues. Splice-variant-specific quantitative Real-Time PCR (qRT-PCR) of SIRT1-FL or SIRT1-DExon8 is shown (Methods), with respect to
expression levels in brain.
doi:10.1371/journal.pone.0013502.g001
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Figure 2. SIRT1-DExon8 is expressed widely in mouse cells and tissues. (A) Mouse SIRT1 splice-variant-specific PCR primers and siRNA.
Schematic of mouse SIRT-FL coding mRNA sequence (737 residues; based on NM_019812.2, GI: 227430307) plus loci of primers used (arrows, below
panel). The novel Exon7/9 splice junction and target loci of siRNA which selectively target mouse SIRT1-DExon8 (xD8*) or mouse SIRT1-FL (xFL*) are
shown above panel. Similar to humans, mouse SIRT1 Exon8 is the largest coding Exon and translation of SIRT1-Exon9 remains in-frame in the mouse
SIRT1-DExon8 transcript, generating a 553 residue protein. For mouse primer and siRNA sequences see Figures S13 and S15. (B) SIRT1-FL versus
SIRT1-DExon8 expression across a range of normal mouse tissues. Mouse splice-variant-specific qRT-PCR of SIRT1-FL or SIRT1-DExon8 with respect to
b-Actin using the delta-C(t) method (see Methods). Data is shown with respect to expression levels in brain. (C) Expression of SIRT1-FL in a panel of
mouse cell lines. Mouse splice-variant-specific qRT-PCR was performed for SIRT1-FL and corrected by b-Actin levels as in (B) above. (D) Expression of
SIRT1-DExon8 in a panel of mouse cell lines. Mouse splice-variant-specific qRT-PCR was performed for SIRT1-DExon8 and corrected by b-Actin levels
SIRT1 Isoforms via Splicing
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Characterization of SIRT1-DExon8 protein expression
Human SIRT1-DExon8 cDNA was cloned and engineered into
a mammalian expression vector containing a CMV promoter and
C-terminal Myc and His tags (Figure S6; Methods). In addition,
we designed human and mouse isoform-specific siRNA against
SIRT1-DExon8 or SIRT1-FL (Figures 1A and 2A) and validated
their isoform selectivity at the mRNA level (Figure S7) and protein
level (see below). Human SIRT1-FL typically displays an apparent
molecular weight of ,116 kDa by SDS-PAGE. Exogenous
expression of SIRT1-DExon8 in human cells gave the expected
,95 kDa SIRT1-DExon8 monomeric protein product detectable
with antibodies directed against the SIRT1 N-terminus (residues
1–131) (Figure 4B), and against the SIRT1 C-terminus (residues
448–747) (Figure 4B). The 95 kDa SIRT1-DExon8 exogenous
protein was also detectable with an antibody directed against the
C-terminal Myc tag (Figure 4B, top panel). These results confirm
that human SIRT1-DExon8 is translated in-frame in vivo.
Importantly a 300 kDa Western blot band was also observed
following exogenous expression of SIRT1-DExon8 in addition to
the expected ‘monomeric’ 95 kDa species described above (data not
shown). We suggest that the SIRT1-DExon8 protein may exist
within a large multi-molecular complex which is resistant to the
denaturing conditions of SDS-PAGE. Partial exposure of SIRT1-
DExon8 protein, otherwise buried within a high molecular weight
complex, would explain our observation that antibodies directed
against discrete SIRT1 domains display differential immuno-affinity
towards endogenous SIRT1-DExon8 protein at 300 kDa (data not
shown). Murine P19 EC cells were found to express high SIRT1-
DExon8 RNA levels (Figures 2C-2E), and selective siRNA-mediated
knockdown of endogenous SIRT1-DExon8 resulted in loss of a
,300 kDa protein band in these cells (Figure 4A). Similarly,
endogenous SIRT1-DExon8 protein also migrated at 300 kDa in
murine fibrosarcoma cells (Figure S8). Future studies will explore
this high molecular weight SIRT1-DExon8 protein complex in
detail. For the present study, we focused on the expected 95 kDa
monomeric SIRT1-DExon8 protein in human cells (see below).
SIRT1-FL is constitutively phosphorylated at serines 27 and 47 in
human cells (S27P and S47P)[Refs 36, 37]. Interestingly, SIRT1-
DExon8 was also phosphorylated at S27 and S47 (Figure 4B),
indicating that native SIRT1-kinase(s) recognise and phosphorylate
the exogenously expressed SIRT1-DExon8 protein.
SIRT1-FL can undergo nucleo-cytoplasmic translocation in a
CRM1-dependent manner due to its N-terminal nuclear localiza-
tion and nuclear export sequences [38]. Cell fractionation
experiments demonstrated that SIRT1-FL and SIRT1-DExon8
proteins display broadly similar sub-cellular localisation (Figure
S9). This suggests that the nuclear-shuttling machinery distributes
the two SIRT1 isoforms in a comparable manner. Taken together
with the phosphorylation of both SIRT1 isoforms at S27 and S47
(Figure 4B), the results collectively suggest that SIRT1-FL and
SIRT1-DExon8 present equivalent N-termini in vivo, despite the
C-terminal deletion of 186 residues in SIRT1-DExon8.
SIRT1-FL and SIRT1-DExon8 display distinct protein half-
lives
Turnover of SIRT1-DExon8 and SIRT1-FL was explored using
time-course analyses following inhibition of cellular protein
synthesis with cycloheximide (CHX; Figure 4C). The results
demonstrated a short half-life of ,2 hours for SIRT1-DExon8
protein compared with .9 hours for SIRT1-FL (Figures 4C and
4D). It is worth considering the fact that the SIRT1-DExon8
transcript displays striking RNA stability (Figure 3E), and is rapidly
induced by stress in a pulse-like manner (Figures 3A and 3B),
whereas SIRT1-DExon8 protein exhibits rapid turnover
(Figures 4C and 4D). This combination may ensure transcript
abundance during stress, while tightly regulating the persistence of
the protein product, a theme reminiscent of several stress response
factors including p53, p63, p73, and c-Jun [14,39,40].
SIRT1-DExon8 Protein-Protein Interactions
SIRT1-FL coordinates multiple processes through direct interac-
tion with, and deacetylation of, numerous important regulatory
proteins. Therefore we investigated the SIRT1-DExon8 protein
interactome to deduce its biological role. Purified endogenous
SIRT1-FL is reported to form homo-trimers in vivo [41], a
characteristic which may be conserved between Sir2-family members
[42]. However SIRT1-FL does not interact with SIRT1-DExon8
(Figure 5A, lower panel, lane6; and Figure 5B). This indicates a
requirement for the Exon8-encoded region to mediate SIRT1-FL-
trimerization in vivo. SIRT1-FL deacetylation activity is fine-tuned
by several mechanisms [43], including interaction with the SIRT1-
FL activator AROS (Active Regulator Of SIRT1–FL)[44], and the
SIRT1-FL-inhibitor DBC-1 (Deleted in Breast Cancer-1)[45,46].
Our immunoprecipitation experiments demonstrated that AROS
can also bind to SIRT1-DExon8 in vivo (Figure 5C), in agreement
with the reported AROS-binding site (SIRT1-residues 114–217)[44]
which is present in both SIRT1-FL and SIRT1-DExon8 (Figure 1B).
In contrast, DBC-1 does not interact with SIRT1-DExon8
(Figure 5D), consistent with the overlap between the DBC-1 binding
site (SIRT1-residues 210–500)[45], and the region which is absent
from SIRT1-DExon8 (SIRT1-residues 452–638; Figure 1B). By
deduction, SIRT1-residues 452–500 may be critical for the SIRT1-
FL-DBC-1 interaction, and/or SIRT1-Exon8-skipping may result in
structural changes which hinder a SIRT1-DExon8-DBC-1 interac-
tion. In summary, (i) SIRT1-DExon8 does not engage in hetero-
trimerization with SIRT1-FL; (ii) SIRT1-DExon8 can bind AROS (a
SIRT1-FL activator); (iii) SIRT1-DExon8 does not bind DBC-1 (a
SIRT1-FL inhibitor).
Thus, the inclusion/exclusion of Exon8 generates significantly
different capacity for SIRT1-protein interactions, raising the
possibility of other distinct interactions and functions for SIRT1-
DExon8 versus SIRT1-FL. In particular, AROS and DBC-1 have
been shown to control the ability of SIRT1-FL to complex with, and
repress, the crucial tumour suppressor p53 [31,32,44–46]. Impor-
tantly, SIRT1-DExon8 also interacted with p53 in vivo (Figures 5D
and 5E), indicating that Exon8-exclusion does not interrupt the
SIRT1-p53 interaction. This is consistent with the retention on
SIRT1-DExon8 of 13 of the 14 critical conserved residues required
for the interaction between a p53 peptide and a SIRT1-homologue
(Figure 1B)[47]. Indeed, it is interesting that the Exon8-encoded
region lies immediately downstream of the reported SIRT1-p53
interacting residues (Figure 1B)[47], such that a distal region of the
SIRT1 C-terminus becomes more proximal to the interaction site in
a p53-SIRT1-DExon8 complex (Figure 1B).
SIRT1-DExon8 regulates p53 acetylation
SIRT1-FL is an NAD-dependent deacetylase of p53 [31,32]. The
deacetylase potential of SIRT1-DExon8 was assessed using a
as in (B) above. (E) Relative expression levels of SIRT1-FL versus SIRT1-DExon8 transcripts in a panel of mouse cell lines. The data in (C) and (D) above,
which represents the relative expression of SIRT1-FL or SIRT1-DExon8 with respect to b-Actin by the delta-C(t) method, was used here to calculate the
true relative ratio of SIRT1-DExon8/SIRT1-FL.
doi:10.1371/journal.pone.0013502.g002
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Figure 3. In contrast to SIRT1-FL, SIRT1-DExon8 displays stress-sensitivity and significant RNA stability. (A) Splice-variant-specific qRT-
PCR was performed as in Figure 1 for SIRT1-FL or SIRT1-DExon8 mRNA levels in HCT116 p53+/+ cells, +/- UV stress treatment as indicated (see:
Methods). (B) The qRT-PCR data in (A) above was plotted to highlight the dose-dependent pulse of SIRT1-DExon8 mRNA induction after stress. (C)
SIRT1-FL mRNA levels in response to stress in vivo. Mouse SIRT1-FL mRNA expression was analysed by qRT-PCR and expressed relative to b-Actin by
the delta-C(t) method in a panel of mouse tissues. Total RNA was harvested 2.5 hours after mock or whole-body c-irradiation with 5 Gy. Data is shown
with respect to levels in control mice for each tissue. (D) SIRT1-DExon8 mRNA levels display stress-induction in vivo. Mouse SIRT1-DExon8 mRNA
expression was analysed by qRT-PCR and expressed relative to b-Actin by the delta-C(t) method in a panel of mouse tissues which were treated as in
(C) above. Data is shown with respect to levels in control mice for each tissue. (E) Transcript stability of SIRT1-FL versus SIRT1-DExon8. qRT-PCR
SIRT1 Isoforms via Splicing
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standard fluorometric in vitro deacetylase assay (see: Methods). In this
assay, the target substrate is a p53 peptide acetylated at Lysine382,
which is a well-documented substrate for SIRT1-FL-mediated
deacetylation [31,32]. As expected, SIRT1-FL displayed robust
deacetylase activity in vitro (Figure 6A). In contrast, SIRT1-DExon8
displayed weak but measurable deacetylase activity (Figures 6A and
S11). Importantly, the presence of SIRT1-FL and SIRT1-DExon8 in
a 1:1 ratio (Figure S10, lane 4) was not inhibitory, instead combining
to produce an additive effect on deacetylation of the p53 peptide, with
deacetylase activity increased ,15% above that of SIRT1-FL alone
(Figure 6A). The deacetylase activity of SIRT1-DExon8 was also
assessed in vivo. Exogenous SIRT1-FL displayed greater deacetyla-
tion of exogenous p53 at K382 than SIRT1-DExon8; however
exogenous expression of both SIRT1-FL plus SIRT1-DExon8
resulted in enhanced deacetylation of p53 in vivo (Figure 6B). Similar
results were observed with endogenous p53 following stress-exposure
(Figure 6C). Conversely, selective siRNA-mediated depletion of
endogenous SIRT1-FL or SIRT1-DExon8 caused increased p53
K382 acetylation, again consistent with a strong deacetylation role for
SIRT1-FL and weak deacetylation by SIRT1-DExon8 (Figure 6D).
In summary, in vivo and in vitro deacetylase results indicated that: (i)
directly or indirectly both SIRT1 isoforms were capable of down-
regulating p53 K382 acetylation; (ii) SIRT1-FL exerted a stronger
effect on p53 K382 acetylation than SIRT1-DExon8; (iii) in
combination, the two SIRT1 isoforms exerted an additive effect.
SIRT1-DExon8 regulates p53 expression and the cellular
stress response
Since both p53 and SIRT1-DExon8 are strongly induced by stress,
we asked if SIRT1-DExon8 might regulate p53 following acute DNA
damage (UV-irradiation) or chronic disturbance of RNA metabolism
(5-FU plus Thymidine). Stress-induced up-regulation of p53
expression levels is well-documented and was observed here as
expected (Figure 6E)[16, 22; reviewed in: 13, 14]. However, depletion
of SIRT1-DExon8 significantly enhanced stress-induced up-regula-
tion of p53 expression levels (Figure 6E), indicating a repressive role
for SIRT1-DExon8 in p53 regulation after stress. Next, given the
central role of p53 in directing the cellular response to stress, and the
ability of SIRT1-DExon8 to repress p53 levels, we also examined the
possibility that SIRT1-DExon8 might influence the cellular response
to stress. Depletion of SIRT1-DExon8 using siRNA prior to exposure
of cells to three different stresses resulted in a markedly more severe
stress phenotype at the whole-cell level (Figure S12). This effect was
quantified using FACS analysis and Annexin V staining which
indicated a significantly increased fraction of cells passing through
early stages of apoptosis if SIRT1-DExon8 was depleted prior to
stress-exposure, compared to stress-exposure alone (Figure 6F).
Taken together, the results suggest an anti-apoptotic role for
SIRT1-DExon8 following stress (Figures 6F and S12), consistent
with a repressive role for SIRT1-DExon8 in p53 regulation after
stress (Figures 6E and 6G).
p53 regulates SIRT1 splicing to complete an auto-
regulatory loop
We reasoned that a decision must be made between
synthesizing SIRT1-FL or SIRT1-DExon8 from the primary
SIRT1 pre-mRNA transcript, and that this decision must be
coordinated with the crucial requirements of the p53 stress
response. Thus, we sought to understand the regulation of SIRT1
splicing.
In human cell experiments using p53 gene knockout (Figure 7A),
siRNA-mediated silencing of p53 expression (Figure 7B), or p53
de-repression by depletion of the p53-repressor E6 (Figure 7C),
SIRT1 splicing clearly displayed p53-dependency. In particular,
SIRT1-DExon8 mRNA expression was selectively attenuated
by p53 before and after stress, in contrast to SIRT1-FL mRNA
levels (Figures 7A–7C). This ability of p53 to selectively repress
SIRT1-DExon8 mRNA expression exhibited conservation be-
tween humans and mice, with increased SIRT1-DExon8
mRNA expression levels evident in the brain, liver and testis of
p532/2 mice compared to their wt p53+/+ control littermates
(Figures 7D and 7E). However, we must point out that comparing
other tissues of p53+/+ and p532/2 mice, the ability of p53 to
repress SIRT1-DExon8 mRNA expression displayed some tissue
specificity, with no effect of p53 knockout on SIRT1-DExon8
levels evident in mouse spleen and heart tissues (Figures 7D and
7E). We next investigated whether p53 affected SIRT1-DExon8
protein levels in addition to SIRT1-DExon8 mRNA expression.
Depletion of p53 via siRNA was associated with increased SIRT1-
DExon8 protein expression (Figure 7F). Conversely, exogenous
SIRT1-DExon8 protein expression was significantly higher in a
p53-null background than when co-expressed with exogenous wt
p53 protein (Figure 7G; see also, above: Figure 6B, lower panel).
In summary, p53 exerted a repressive effect on expression levels of
the SIRT1-DExon8 protein, consistent with p53-dependent
repression of SIRT1-DExon8 mRNA levels (see above). Therefore,
since p53 can repress SIRT1-DExon8 (Figure 7), while in
reciprocal SIRT1-DExon8 can repress p53 acetylation and
expression (Figure 6), the results collectively suggest a p53-
SIRT1-DExon8 feedback loop whereby p53 auto-regulates its
expression levels via p53-dependent SIRT1 splice variation
(Figure 7H).
Discussion
Here we characterize the first alternative SIRT1 isoform. In
mammals, multiple copies of the sequence motif UAGG in any
single Exon are associated with skipping of that Exon by alternative
splicing [49,50]. In SIRT1, the only coding Exon which contains
the UAGG motif is SIRT1-Exon8 (human Exon8 =4 copies;
mouse Exon8 =4 copies), consistent with evolutionary conservation
of SIRT1 Exon8 skipping, as shown here in human and mouse
SIRT1.
SIRT1-FL protein has a predicted molecular weight of 81 kDa,
however it is observed at 116 kDa by SDS-PAGE analysis.
Accordingly, monomeric SIRT1-DExon8 protein is predicted to
migrate at ,95 kDa by SDS-PAGE. We detected SIRT1-DExon8
protein at 95 kDa and 300 kDa in human epithelial cells
(Figure 4B and data not shown), while it migrated at 300 kDa in
mouse fibroblast and embryonic lineages (Figures 4A and S8). This
may be explained by the possible involvement of SIRT1-DExon8
in detergent-resistant higher molecular weight complexes which
exhibit species-specific and/or tissue-specific differences. Consis-
specific for SIRT1-FL or SIRT1-DExon8 was performed as above at intervals following transcriptional inhibition using Actinomycin D (see Methods).
Initial expression levels of each transcript = 100%. Results shown are for HCT116 p532/2 cells. Similar results were observed for HCT116 p53+/+,
p53+/2 and ARPE19 cells (data not shown). (F) Down-regulation of the SC35 splicing factor correlates with a selective increase in SIRT1-DExon8
expression. On the left, siRNA-mediated SC35 protein knockdown was performed in HCT116 human cells and verified by Western blot, followed by
transcript-specific qRT-PCR for SIRT1-FL or SIRT1-DExon8. On the right, HCT116 cells were exposed to 10 J/m2 UV-irradiation and harvested 6 hours
later. SC35 protein levels and qRT-PCR for SIRT1-FL or SIRT1-DExon8 were quantified as above.
doi:10.1371/journal.pone.0013502.g003
SIRT1 Isoforms via Splicing
PLoS ONE | www.plosone.org 7 October 2010 | Volume 5 | Issue 10 | e13502
Figure 4. Similarities and differences in SIRT1-DExon8 versus SIRT1-FL proteins. (A) Validation of endogenous SIRT1-DExon8 protein
expression. Mouse P19 EC cells were transfected with the indicated siRNAs. 48 hours later, cells were analysed by Western blot for SIRT1 expression in
whole cell lysates using a rabbit polyclonal anti-SIRT1 N-terminal specific antibody (SIRT1 residues 1-131), with b-Actin as a loading control. Different
exposures are shown to aide visualisation of SIRT1-FL and SIRT1-DExon8 proteins and to highlight their relative expression. (B) SIRT1-DExon8 can be
expressed as a protein and phosphorylated at S27 and S47. Myc-tagged SIRT1-DExon8 was transiently expressed in HCT116 cells and total cell lysates
were probed with an array of antibodies. The C-terminal Myc-tag was probed with anti-c-Myc antibody (top panel), and detects SIRT1-DExon8 at
,95 kDa. Lower panels were probed with SIRT1 antibodies and therefore detect endogenous SIRT1-FL (,116 kDa, upper band) and exogenous
SIRT1-DExon8 (,95 kDa, lower band). Lysates were also probed using a C-terminal-specific SIRT1 antibody (residues 448–747), a N-terminal-specific
SIRT1 antibody (residues 1–131), and phospho-specific antibodies for phosphorylated SIRT1-serine27 (S27P) or phosphorylated SIRT1-serine47 (S47P).
(C) SIRT1-DExon8 protein has a short half life compared to SIRT1-FL. Western blots monitor decreases in protein level at intervals following treatment
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tent with this, both Sir2p (the yeast homologue of SIRT1) and
SIRT6 (a mammalian Sirtuin family member) are known to
participate in large multi-protein complexes [51,52], while tissue-
specific SIRT1 functions have also been reported [53,54].
Additional uncharacterized SIRT1 bands have also been observed
by Western blot in brain, thymus, lung and testis tissues [54–56],
consistent with the tissues where we observed higher levels of
SIRT1-DExon8 expression (Figures 1D and 2B); however,
whether these bands represent SIRT1-DExon8 or indeed arise
by alternative splicing remains unclear at this point. Taken
together with our report, the emerging evidence suggests that the
ability of SIRT1 to regulate mammalian biology at several levels
may be partially explained by the existence of alternate SIRT1
isoforms, such as SIRT1-DExon8.
p53 expression levels and activity dictate p53-dependent stress-
responses, tumour suppression, and whether p53 is pro- or anti-
ageing, while SIRT1 is implicated in the regulation of p53, ageing
and the stress response (see: Introduction). It is therefore notable
that the newly discovered splice variant SIRT1-DExon8 is stress-
responsive (Figure 3), p53-dependent (Figure 7) and can regulate
p53 in reciprocal (Figure 6). This reveals novel auto-regulatory
feedback between p53 and SIRT1, key factors in the common
biology of stress, cancer, metabolism, and ageing. Importantly, the
kinetics of SIRT1-DExon8 stress-induction (Figures 3A and 3B)
overlap with its ability to regulate p53 acetylation, p53
accumulation and the cellular stress response (Figure 6). Stress-
induction of SIRT1-DExon8 is also consistent with the numerous
stress-responsive roles which have been demonstrated previously
for SIRT1 in promoting DNA repair and stress tolerance
[8,57,58]. Similarly, caloric restriction (CR) is reported to induce
SIRT1 expression, for example in kidney cells [59]. Therefore it
would be interesting to examine the effect of CR on SIRT1-
DExon8 expression in kidney, as this tissue exhibited the largest
stress-induction of SIRT1-DExon8 in mice (Figure 3D). Significant
potential exists for differential regulation of the p53 stress response
by SIRT1-FL and SIRT1-DExon8 given that: (i) SIRT1-DExon8
is stress-responsive but SIRT1-FL is not (Figures 3A-3D); (ii)
SIRT1-DExon8 displays differential RNA stability and protein
stability versus SIRT1-FL (Figures 3E, 4C and 4D); (iii) SIRT1-
DExon8 and SIRT1-FL also display differential capacity to
interact with AROS (a SIRT1-activator which promotes p53-
deacetylation)[44] or DBC-1 (a SIRT1-inhibitor which promotes
p53-acetylation)[45,46](Figures 5C and 5D). More generally, it is
likely that SIRT1-FL and SIRT1-DExon8 perform distinct cellular
roles since phosphorylation has emerged as an important regulator
of SIRT1-FL function [37,43,60]. Thus, divergent regulation of
the two SIRT1 isoforms may arise via differential phosphorylation
of SIRT1-FL versus SIRT1-DExon8, since the Exon8-encoded
region contains several novel phosphorylated residues which are
substrates for stress-signaling kinases and a cyclinB/cdk1 docking
site [60]. In contrast, the stress-activated CK2 kinase was shown to
dictate SIRT1-FL deacetylation activity, substrate-affinity, and
SIRT1-FL-dependent cellular stress-tolerance through phosphor-
ylation at Ser 154, 649, 651 and 683, all of which are retained on
SIRT1-DExon8 [61].
Although SIRT1-DExon8 displays partial deletion of the
deacetylase domain, it retains some deacetylation activity
(Figure 6). The deacetylase experiments used here employ p53
acetylated at Lys382 as a well-defined target substrate. However in
vivo, SIRT1-FL has numerous other target substrates, to which
SIRT1-DExon8 may have differential affinity or may deacetylate
to a greater or lesser extent. Similarly, in vivo conditions will differ
from the in vitro deacetylase assay, for example, substrate and
NAD concentrations are in excess in vitro. Propionylation and
butyrylation of lysine residues are highly novel protein post-
translational modifications with as-yet unknown purposes, but
which are chemically similar to acetylation [62]. In addition to
deacetylation, SIRT1-FL was recently reported to also perform
de-propionylation and de-butyrylation of C-terminal Lysines on
p53 [63] and Histone H3 Lys23 [64], although currently, it
remains unclear how SIRT1-FL differentiates between these
reactions. While the internal deletion of SIRT1-DExon8 attenu-
ates its deacetylation of p53, the possibility remains that it may
favour a role for SIRT1-DExon8 in other processes such as de-
propionylation or de-butyrylation. On a different note, SIRT1-FL
has been reported to possess deacetylation-independent functions,
such as inhibition of NFkB activity [65], stimulation of the
methyltransferase SUV39H1 [66], and repression of the epithelial
Na+-channel alpha sub-unit [67]. Interestingly, these deacetyla-
tion-independent functions require only the SIRT1 N-terminus
[65-67], a region which remains intact in SIRT1-DExon8.
Similarly, SIRT1-dependent neuroprotection against low potassi-
um conditions can also be conferred by deacetylase-dead SIRT1-
FL mutant proteins [68]. Taken together, these reports raise the
possibility that SIRT1-DExon8 could influence p53 and whole-cell
behaviour despite its weak deacetylase activity via deacetylase-
independent functions.
The mechanism underlying p53-dependent SIRT1 splicing
remains unclear. However, p53 can bind to single-stranded RNA
with ,100-fold higher affinity than double-stranded DNA in vitro
[69]. Moreover, several studies describe direct RNA binding by
p53 suggesting a general role in RNA regulation, for example
inhibition of RNA helicases, modification of RNA secondary
structures, and catalysis of RNA-annealing [70-73]. So, although
p53 has been primarily characterised as a DNA-binding
transcription factor, p53 also possesses the capacity to interact
directly with RNA and may therefore be in a position to directly
regulate SIRT1 RNA splicing. Alternatively, given our results
indicating a role for the splicing factor SC35 in the regulation of
SIRT1-DExon8 splicing (Figure 3F), we are also currently
exploring the possibility that p53 might influence RNA processing
through modulation of the SR-family of splicing factors.
p53 and SIRT1 both influence development, for example
during embryonal stages and in neuronal tissues [6,8,16–18],
where RNA splicing also has a central role [34,74]. In addition,
p53 and SIRT1 influence metabolic processes, such as respiration
efficiency, glucose and lipid metabolism, and metabolic shifts
during dietary restriction [1–5,21]. Therefore the existence of an
auto-regulatory loop involving p53-dependent modulation of
SIRT1 alternative splicing may provide insight into the coordi-
nation of these complex processes. Significant debate currently
exists regarding whether SIRT1 is a tumour-promoter or a
tumour-suppressor, and whether SIRT1 can mediate lifespan
extension via caloric restriction in higher organisms. Our
of HCT116 cells with cycloheximide (CHX) to halt protein synthesis. SIRT1-FL and SIRT1-DExon8 were probed with using either the myc-tag or anti-
SIRT1 antibodies as in (B) above. Levels of p53, JNK2 and Actin were probed in the same samples to provide internal controls displaying their
expected protein turnover. (D) Graphs summarize the Western blot data (from C, above) by densitometry for levels of total SIRT1 protein, or
phosphorylation at S27 or S47. Data is expressed with respect to the highest signal in the corresponding immuno-blots in (C). In each case the half-
life is indicated.
doi:10.1371/journal.pone.0013502.g004
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Figure 5. SIRT1-DExon8 interacts with AROS and p53, but does not interact with SIRT1-FL or DBC-1. (A) SIRT1-DExon8 and SIRT FL
proteins do not physically interact. Myc/His-tagged SIRT1-DExon8, SIRT1-FL or empty vector were exogenously expressed in HCT116 cells followed by
affinity purification of the His-tag. Eluates were probed by Western blot for enrichment of Myc-tagged SIRT1-FL and SIRT1-DExon8 (upper panel; anti-
c-Myc). Lysates were also probed with a C-terminal specific polyclonal SIRT1 antibody (residues 448-747) to visualize endogenous SIRT1-FL in addition
to the exogenous SIRT1-FL and SIRT1-DExon8 proteins. (B) SIRT1-DExon8 and SIRT FL proteins do not physically interact. Myc-SIRT1-DExon8 was
exogenously expressed in HCT116 cells, and cell lysates were immuno-precipitated with anti-c-Myc antibody. Western-blotting was performed with a
C-terminal anti-SIRT1 antibody (residues 448–747) as in (A) above. * indicates a non-specific band. (C) SIRT1-DExon8 interacts with AROS. Myc-SIRT1-
DExon8 and Flag-AROS were exogenously expressed in HCT116 cells, and the Flag epitope was immuno-precipitated. In the eluate, AROS was
detected by probing with an anti-AROS antibody, while the interaction with SIRT1-DExon8 was probed with anti-c-Myc antibody. (D) SIRT1-DExon8
interacts with p53, but not DBC-1. Myc-SIRT1-DExon8 was exogenously expressed in HCT116 cells and immuno-precipitated as in (B) above. Eluates
were probed for endogenous p53 (anti-p53 DO-1) or endogenous DBC-1 (anti-DBC-1) to assay for interactions with SIRT1-DExon8 in vivo. (E) SIRT1-
DExon8 interacts with p53. Myc-SIRT1-DExon8 or empty vector were exogenously expressed in HCT116 cells. Whole cell lysates were immuno-
precipitated using a polyclonal anti-p53 (FL-393) antibody, followed by Western blotting of eluates for p53 (DO-1, lower panel) or Myc-SIRT1-DExon8
with anti-c-Myc antibody.
doi:10.1371/journal.pone.0013502.g005
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Figure 6. SIRT1-DExon8 represses p53acetylation, p53 accumulation and the cellular response to stress. (A) SIRT1-DExon8 displays
weak deacetylase activity in vitro and is additive with SIRT1-FL. SIRT1-DExon8, SIRT1-FL or empty vector were exogenously expressed in HCT116 cells
followed by affinity purification as in Figure 5A above. In the fluorometric deacetylase assay, the initial reaction rate for each condition was calculated
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discovery of alternate SIRT1 isoforms with distinct characteristics
provides important insight into SIRT1 function and may provide
an explanation for previous apparently conflicting results.
Similarly, numerous other SIRT1-attributed functions (see:
Introduction) may in fact be distributed between SIRT1-FL and
SIRT1-DExon8, working independently or in synergy. Novel
therapeutics targeting specific SIRT1 isoforms may enable tailored
manipulation of p53 or SIRT1 functions in a wide variety of
disease states.
Materials and Methods
Ethics Statement
Mice were treated in accordance with the Spanish Laws and the
Guidelines for Humane Endpoints for Animals Used in Biomed-
ical Research. The Spanish National Cancer Research Centre
(CNIO) is part of the ‘‘Carlos III’’ Health Institute (ISCIII) and all
protocols were previously subjected and approved by the Ethical
Committee of the ISCIII; approval ID numbers: PA-45 v2, PA-
312 and PA-130/07.
Mouse Experiments
p53+/+ and p53-/- mice of pure C57BL6 genetic background
[75] were housed in a pathogen-free barrier area under standard
conditions. 14-week-old mice were exposed to 5 Gy of whole-body
c-irradiation and sacrificed +2.5 hours after stress-exposure for
immediate tissue harvest.
Cell culture and treatments. p53+/+, p53+/2 and p532/2
isogenic clones derived from human HCT116 colorectal epithelial
cancer cells [76] were a gift from Dr. Bert Vogelstein (John Hopkins
University). ARPE19 normal human non-transformed retinal
epithelial cells [77] were purchased from ATCC. All cells used in
this study were cultured according to the corresponding ATCC
guidelines: WI-38, HT-29, HT-1080, LoVo, RKO, MCF-7,
TOV112D, SW48, SW480, SW620, DLD-1, U2OS, SAOS-2,
SiHa, wt MEFs, ARF KO MEFs, mouse P19 Embryonal
Carcinoma cells. Mouse JGA 95.2 Fibrosarcoma cells were derived
in the Tumour Suppression Laboratory, CNIO, Spain. Cells were
treated with 200 nM Actinomycin D (Sigma, A9415) to inhibit
transcription (Figures 3E and S5), as described [78]. UV-irradiation
was performed as described [79], delivering 0 (control), 5, 10 or 20 J/
m2 of UV-irradiation as indicated in each Figure. 5-FU was used at
375 mM and Thymidine was used at 425 mM (Figures 6E and S12).
Protein half-life experiments using 100 mg/mL cycloheximide
(Figures 4C and 4D) as described [37]. Cells passing through the
early stages of apoptosis were quantified by fluorescence-activated cell
sorting (FACS) using Annexin V-Fluos (Roche) as described [80].
Transfection and siRNA sequences. Transfection of
siRNA (all from Dharmacon) and/or DNA expression constructs
were carried out as described [80,81]. Sequences and target loci of
all human and mouse siRNA are detailed in Figure S13.
RNA, RT-PCR and primer sequences. Total RNA and
oligo-dT-purified polyA-tailed mRNA were isolated as described
[22]. Normal human tissue total RNA samples were purchased
from AMS Biotechnology (Europe). Normal mouse tissue total
RNA samples were prepared as follows: whole tissues were snap-
frozen in liquid nitrogen immediately after mouse sacrifice. Tissue
total RNA was extracted by the standard Trizol method
(Invitrogen #15596-026) using a polytron homogenizer, followed
by phenol-chloroform separation and iso-propyl alcohol
precipitation. RT-PCR and real-time quantitative RT-PCR
(qRT-PCR) were performed for 30–45 cycles as described [22].
All human qRT-PCR data in this study represent the mean +/2
standard deviation of three determinations. Also, expression of
SIRT1-FL and SIRT1-DExon8 mRNA levels was calculated
relative to the housekeeper b-Actin using the delta–C(t) method in
mouse tissues and cell lines. The loci of all human primers used for
SIRT1 RT-PCR in this study are depicted in Figure 1A (human
primer sequences are listed in Figure S14). Human SIRT1 splice-
variant-specific primers were as follows: SIRT1-FL –Forward:
Ex7/8F; Reverse: Ex8R. For specific PCR amplification of
SIRT1-DExon8 -Forward: Ex6F; Reverse: Ex7/9R. The primers
used for co-amplification of SIRT1-FL plus SIRT1-DExon8 in
Figure 1C and Figures S1, S4 and S5, were: Forward: Ex7F;
Reverse: Ex9R. Equivalent RNA loading was routinely assessed in
RT-PCR samples by monitoring GAPDH and LaminA/C
housekeeper mRNA levels with primers as described [81].
The loci of all mouse primers used for SIRT1 RT-PCR in this
study are depicted in Figure 2A (mouse primer sequences are listed
in Figure S15). Mouse SIRT1 splice-variant-specific primers were
as follows: SIRT1-FL –Forward: Ex7/8F; Reverse: Ex8R. For
specific PCR amplification of SIRT1-DExon8 -Forward: Ex6F;
Reverse: Ex7/9R. For co-amplification of SIRT1-FL plus SIRT1-
DExon8 in Figure S3, primers were: Forward: Ex7F; Reverse:
Ex9R. We also monitored total SIRT1 mRNA levels (data not
shown) using the primer pair: Forward: Ex1F; Reverse: Ex2R (see
Figure 2A). PCR products were visualised on a UV transillumi-
nator using 1.2% Agarose gel electrophoresis and 200 ng/mL
ethidium bromide (Sigma, A9415). Sequencing was performed by
MWG Biotech.
Expression Constructs. pcDNA3 mammalian expression
vector encoding Flag-tagged human AROS [44] was kindly
provided by Eun-Joo Kim and Soo-Jong Um, Sejong University,
Seoul, Korea. Cloning of SIRT1-FL and SIRT1-DExon8: from
HCT116 p532/2 cells was performed in a two step process due to
the high GC-content of Exon1 (Cloning strategy, Figure S6). In the
first step, the first four Exons were amplified by RT-PCR and cloned
in TOPO cloning vector, pCR2.1 (Invitrogen) using forward primer
(Methods) and expressed as a percentage of the rate obtained for purified SIRT1-FL alone. (B) Analysis of SIRT1-DExon8 deacetylase activity by
exogenous expression in vivo. Human HCT116 p532/2 cells were transfected as indicated and whole cell lysates were probed for SIRT1 expression
with a rabbit polyclonal anti-SIRT1 N-terminal specific antibody (residues 1–131). Total levels of p53 and p53 acetylation at Lysine 382 (p53 K382Ac)
were also probed. The relative intensity of p53 K382 acetylation was quantified and corrected by the total amount of p53 present using densitometry.
(C) Analysis of SIRT1-DExon8 deacetylase activity following cell stress in vivo. Human HCT116 p53+/+ cells were transfected as indicated and whole
cell lysates were analysed by Western blotting for SIRT1, total p53, and p53 K382Ac levels exactly as in (B) above, in addition to densitometry to
quantify the relative intensity of p53 K382 acetylation. (D) Selective silencing of SIRT1-FL or SIRT1-DExon8 has distinct effects on p53 acetylation.
HCT116 cells were transfected with SIRT1-isoform-specific siRNA to specifically knockdown SIRT1-FL or SIRT1-DExon8 (Methods). Total cell lysates
were probed for endogenous SIRT1-FL (anti-SIRT1 C-terminal residues 448-747), for endogenous p53 (anti-p53 DO-1), and for p53 acetylation at K382
(p53 K382Ac). b-Actin was probed as a loading control. (E) Depletion of SIRT1-DExon8 levels correlates with enhancement of p53-accumulation after
stress. Western blots for p53 and b-Actin are shown in human ARPE19 cells which were treated as indicated and harvested 24 hrs after stress
exposure (for experimental overview, see Figure S12). (F) Depletion of SIRT1-DExon8 levels correlates with enhanced apoptosis after stress. Cells were
treated exactly as in (E) above. Following cell harvest, Annexin V-staining and FACS analysis were performed to quantify the percentage of cells
passing through the early stages of apoptosis. (G) Schematic summary of this figure: both SIRT1-FL and SIRT1-DExon8 can repress p53.
doi:10.1371/journal.pone.0013502.g006
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Figure 7. p53 represses SIRT1-DExon8, completing a p53-SIRT1-DExon8 auto-regulatory feedback loop. (A) SIRT1-FL and SIRT1-DExon8
mRNA expression by qRT-PCR in HCT116 p53 knockout isogenic clones +24 hrs after mock or UV stress treatment (with 10 J/m2), using with polyA-
tailed mRNA as template. Similar results were obtained using total RNA as template (data not shown). (B) The p53-SIRT1-DExon8 axis was analysed in
ARPE19 normal human epithelial cells following treatments as indicated (UV-irradiation with 10J/m2), followed by analysis of SIRT1-DExon8 mRNA
levels by qRT-PCR and Western blotting for total p53, with b-Actin as loading control. (C) Abrogation of HPV-16 E6-mediated repression of p53 levels,
results in down-regulation of SIRT1-DExon8 mRNA levels. Lower panel: HPV-16-infected human cervical epithelial SiHa cells were transfected with
siRNA to deplete the HPV-protein E6, resulting in de-repression of p53 protein expression. b-Actin used as loading control. SIRT1-FL and SIRT1-
DExon8 mRNA levels were also measured by qRT-PCR. Increased p53 expression following E6-depletion correlated with selective down-regulation of
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SIRT1-BamF1 with BamHI linker (59-GTCGAGCGGGAGCAG-
AGGAGGC-39) and the reverse primer SIRT1-R5 (59-CATC-
GCTTGAGGATCTGGAAG-39). A BamHI/EcoRV fragment
from a pCR2.1 plasmid was shuttled to pBSK+. The remaining
parts of SIRT1-FL and SIRT1-DExon8 without stop codons were
amplified by using forward primer SEx2 (59-GTGAAAGTG-
ATGAGGAGGATAG-39) and reverse primer SIRT1-rRV with
EcoRV linker (59-GCGATATCTGATTTGTTTGATGGATAG-
TTCATG-39) and joined in the BglII/EcoRV-cut pBSK+ plasmid.
Both SIRT1-FL and SIRT1-DExon8 were then shuttled across
pcDNA3.1MycHis plasmid (Invitrogen).
Total cell lysate protein preparation, SDS-PAGE, and immuno-
blotting: as described [80,82], except Cell Signaling antibodies,
where supplier’s protocol was followed precisely. The antibodies
used in this study are listed in Figure S16. Cell fractionation was
performed using nuclear and cytoplasmic extraction reagents (NE-
PER kit, Thermo Scientific). Western blotting visualisation by
ECL (Roche). For densitometry, Western blot protein band
intensity was quantified and corrected by the corresponding b-
Actin or total p53 internal control using ‘‘Quantity One v.4.5’’
image analysis software (Biorad).
Immunoprecipitations: for Myc-tagged SIRT1 constructs
(Figures 5B and 5D), Mammalian c-Myc Tag IP/Co-IP kit from
Pierce (#23625) was used. Immunoprecipitation of FLAG-AROS
(Figure 5C) used FLAG-tagged protein immunoprecipitation kit
(Sigma, FLAGIPT1), with elution using FLAG-peptide. Immuno-
precipitation for Figure 5E was as described [80] using ProteinG-
Sepharose Fast Flow beads (Sigma #P-3296).
In vitro deacetylase assay: was performed on SIRT1-FL or
SIRT1-DExon8 proteins which had been expressed in, and
purified from, human HCT116 cells. The assay was performed
according to the manufacturer’s protocol (Abnova #KA0105),
including no-enzyme, no NAD and no-substrate controls (data not
shown). The reaction rate was calculated from the slope of the
linear regression best-fit line to each curve during the linear phase
of the reaction for each condition in the fluorometric deacetylase
assay.
Supporting Information
Figure S1 An additional SIRT1 transcript is revealed by RT-
PCR with multiple primer pairs. PCR primers, with target loci as
indicated in Figure 1A, were used in pairs to co-amplify SIRT1-FL
and SIRT1-DExon8 transcripts from total RNA from human
HCT116 cells. PCR products were analysed by agarose gel
electrophoresis. The expected band sizes for amplification from
SIRT1-FL and the observed band sizes are indicated below the
panel. In each lane the upper band is the expected SIRT1-FL
amplicon, while sequencing of the lower band confirmed a SIRT1
transcript lacking precisely Exon8 only (data not shown). M =
DNA ladder as marker lane. N = Negative controls using no
input RNA.
Found at: doi:10.1371/journal.pone.0013502.s001 (1.23 MB TIF)
Figure S2 SIRT1-FL versus SIRT1-DExon8 expression in a
panel of human epithelial cell lines of normal- or cancer-origin.
Relative expression of SIRT1 splice variants in a variety of human
normal and cancer cell lines. Results show splice-variant-specific
qRT-PCR of SIRT1-FL or SIRT1-DExon8 (see Methods).
Found at: doi:10.1371/journal.pone.0013502.s002 (0.72 MB TIF)
Figure S3 An additional SIRT1 transcript is revealed by RT-
PCR with multiple primer pairs in Mouse cells. Mouse PCR
primers, with target loci as indicated in Figure 2A, were used in
pairs to amplify SIRT1-FL and/or SIRT1-DExon8 transcripts
from total RNA from MEFs. PCR products were analysed by
agarose gel electrophoresis. The expected band sizes are indicated
below the panel. The presence of two bands generated with the
primer pair in Lane 1 correlates exactly with the expected
amplicon from SIRT1-FL (upper band), and a SIRT1 transcript
lacking precisely Exon8 only (lower band). The other lanes
demonstrate splice variant specific RT-PCR for SIRT1-FL or
SIRT1-DExon8. M = DNA ladder as marker lane. N = Negative
controls using no input RNA.
Found at: doi:10.1371/journal.pone.0013502.s003 (1.43 MB TIF)
Figure S4 The kinetics of SIRT1-DExon8 stress-induction are
dose-dependent. RT-PCR co-amplification of SIRT1-FL and
SIRT1-DExon8 (two bands, see: Methods) reveals the rapid
kinetics of SIRT1-DExon8 mRNA induction after UVstress in
HCT116 cells. Also, higher stress insult correlates with greater
SIRT1-DExon8 induction, significantly altering the relative
abundance of the two SIRT1 transcripts. The results correlate
with the specific qRT-PCR of SIRT1-FL or SIRT1-DExon8
shown in Figure 3A.
Found at: doi:10.1371/journal.pone.0013502.s004 (1.48 MB
TIF)
Figure S5 SIRT1-FL versus SIRT1-DExon8: relative abun-
dance and mRNA stability. HCT116 cells were incubated in the
presence of the transcriptional inhibitor Actinomycin D (see:
Methods) and total RNA was harvested at intervals for RT-PCR
analysis. SIRT1-FL and SIRT1-DExon8 were co-amplified (see:
Methods) to monitor changes in their relative abundance. The
results correlate with the specific qRT-PCR of SIRT1-FL or
SIRT1-DExon8 shown in Figure 3E: following transcriptional
inhibition, levels of SIRT1-FL mRNA decay rapidly whereas
SIRT1-DExon8 levels are increased.
Found at: doi:10.1371/journal.pone.0013502.s005 (1.48 MB TIF)
Figure S6 Cloning and expression of SIRT1-FL and SIRT1-
DExon8. Strategy of cloning SIRT1 and SIRT1-D8 in mamma-
lian expression plasmid. Both SIRT1 and SIRT1-D8 were
amplified from HCT116 p53-/- cells by RT-PCR in a two step
process (see: Methods).
Found at: doi:10.1371/journal.pone.0013502.s006 (0.66 MB TIF)
SIRT1-DExon8 mRNA levels. (D) SIRT1-FL mRNA levels are independent of p53 expression in vivo. Mouse SIRT1-FL mRNA expression was analysed by
qRT-PCR and expressed relative to b-Actin by the delta-C(t) method in a panel of mouse tissues from wt p53+/+mice and p532/2 littermates. Data is
shown with respect to levels in p53+/+ mice for each tissue. (E) SIRT1-DExon8 mRNA levels are dependent on p53 expression in vivo. Mouse SIRT1-
DExon8 mRNA expression was analysed by qRT-PCR and expressed relative to b-Actin in tissues from wt p53+/+mice and p532/2 littermates exactly
as in (D) above. (F) SIRT1-DExon8 protein levels are repressed by p53 in vivo. ARPE19 normal human epithelial cells were transfected with control or
p53 siRNA. 48 hours later, the cells were transfected with SIRT1-DExon8 and the protein levels of SIRT1-DExon8, p53 and b-Actin were analysed by
Western blot (left panels). The increase in SIRT1-DExon8 protein levels associated with p53 depletion was quantified by densitometry (right panels).
(G) SIRT1-DExon8 protein levels are repressed by p53 in vivo. Human HCT116 p532/2 cells were transfected as indicated and whole cell lysates were
probed 24 hours later for SIRT1 expression with a rabbit polyclonal anti-SIRT1 N-terminal specific antibody (residues 1–131). Total Histone H3 levels
were also probed as a loading control. (H) A schematic which summaries the reciprocal relationship between p53 and SIRT1-DExon8. A p53-SIRT1-
DExon8 auto-regulatory feedback loop is observed, whereby p53 can represses SIRT1-DExon8 expression (Figures 7A–7G) and SIRT1-DExon8 can
repress p53 (Figures 6A–6E).
doi:10.1371/journal.pone.0013502.g007
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Figure S7 Selective silencing via siRNA. Splice-variant-specific
depletion of human SIRT1-FL or SIRT1-DExon8 was achieved
using the siRNA shown in Figure 1A. HCT116 cells were
transfected with siRNA targeting human SIRT1-FL or SIRT1-
DExon8 (see: Methods). Transcript levels of SIRT1-FL (lower
panel) or SIRT1-DExon8 (upper panel) were measured by qRT-
PCR and corrected for loading using the mRNA levels of the
housekeeper GAPDH. Data = Mean +/- Std Deviation of 3
determinations.
Found at: doi:10.1371/journal.pone.0013502.s007 (0.65 MB TIF)
Figure S8 Detection of endogenous SIRT1-DExon8 protein in
mouse fibrsarcoma cells. Mouse Fibrosarcoma cells were trans-
fected with the siRNA indicated. Whole cell lysates were prepared
as described in Methods, analysed by SDS-PAGE and blotted
using an anti-SIRT1 (1-131) N-terminalspecific antibody. Blots
were also probed for b-Actin as an internal loading control.
Found at: doi:10.1371/journal.pone.0013502.s008 (1.46 MB TIF)
Figure S9 Biochemical fractionation to analyse the subcellular
localisation of SIRT1-DExon8 and SIRT1-FL proteins. Human
HCT116 cells were transfected with SIRT1-DExon8 or SIRT1-FL
and subjected to biochemical fractionation +24 hours afterwards
(Methods). Western blotting of each fraction for SIRT1-DExon8
or SIRT1-FL was performed using their Myc-tag, with equal cell
numbers loaded in each lane. Blotting for Lamin A/C, p53 and
Histone H3 was also performed as as internal controls indicating
successful fractionation. A moderate difference was discernible in
the nuclear soluble fraction between SIRT1-FL and SIRT1-
DExon8.
Found at: doi:10.1371/journal.pone.0013502.s009 (0.96 MB TIF)
Figure S10 Analysis of the expression levels of purified His-
SIRT1-FL and His-SIRT1-DExon8 for use in the deacetylase
assay. HCT116 cells were transfected with the constructs
indicated, followed by His-tag immunoprecipitation via Ni-
Agarose columns as described in Methods. The levels of SIRT1-
FL and SIRT1-DExon8 in the eluates were analysed by SDS-
PAGE and blotting for the c-MYC tag.
Found at: doi:10.1371/journal.pone.0013502.s010 (0.91 MB TIF)
Figure S11 SIRT1-DExon8 has weak deacetylase activity in
vitro. HCT116 cells were transfected with empty vector or SIRT1-
DExon8, followed by His-tag immunoprecipitation via Ni-Agarose
columns as described in Methods(see also: Supplementary Figure
10). This data is reproduced from Figure 6A, but here only
SIRT1-DExon8 and the vector-only control are shown. Deacety-
lase activity of purified SIRT1-DExon8 protein was analysed by
the fluorometric deacetylase assay and was greater than the
background signal in the vector-only control. The table shows the
reaction rate as a percentage of the deacetylase activity of SIRT1-
FL (see: Figure 6A). The reaction rate was the slope of the linear
regression best-fit line to each curve during the linear phase of the
reaction.
Found at: doi:10.1371/journal.pone.0013502.s011 (0.68 MB TIF)
Figure S12 SIRT1-DExon8 displays an anti-apoptotic role after
stress. ARPE19 cells were treated with siRNA for 48 hrs, then
mock-treated or exposed to stress as indicated. Photographs taken
+24 hrs after stress exposure.
Found at: doi:10.1371/journal.pone.0013502.s012 (3.82 MB TIF)
Figure S13 siRNA sequences used in this study. All siRNA are
written in sense orientation 59-39.
Found at: doi:10.1371/journal.pone.0013502.s013 (0.72 MB TIF)
Figure S14 Human PCR primer sequences used in this study.
Found at: doi:10.1371/journal.pone.0013502.s014 (0.73 MB TIF)
Figure S15 Mouse PCR primer sequences used in this study.
Found at: doi:10.1371/journal.pone.0013502.s015 (0.73 MB TIF)
Figure S16 Antibodies used in this study.
Found at: doi:10.1371/journal.pone.0013502.s016 (0.79 MB TIF)
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